|Bid||0.0580 x 2176800|
|Ask||0.0590 x 11417600|
|Day's range||0.0530 - 0.0590|
|52-week range||0.0250 - 0.0640|
|Beta (5Y monthly)||0.84|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
In this Open Briefing(R) interview, Bluechiip Limited (ASX:BCT) (FRA:1BL) MD Andrew McLellan discusses the September quarter 4C, License and Development agreement with US-based Fujifilm Irvine Scientific and the first sales of Bluechiip's own consumables.
Bluechiip Limited (ASX:BCT) (FRA:1BL) is pleased to release its Appendix 4C - Quarterly Cashflow report and update for the quarter ended 30 September 2021.
Bluechiip Limited (ASX:BCT) (FRA:1BL), a leader in the development of sample tracking technology for cryogenic environments, today announced that it has signed a two-year Licence and Development Agreement with California-based FUJIFILM Irvine Scientific, Inc. (FISI).